What caused INFU's Q3 2024 earnings to exceed forecasts?

**InfuSystem's Q3 2024 earnings exceeded forecasts due to strong revenue growth in both Patient Services and Device Solutions segments.** 1. **Revenue Growth in Patient Services**: This segment experienced a 5% increase in revenue, reaching $80.4 million. The growth can be attributed to the company's focus on delivering complex durable medical equipment directly to patients, ensuring continuous care at home or other non-hospital settings. 2. **Revenue Growth in Device Solutions**: This segment saw an 11% increase in revenue, reaching $54.5 million. The growth is likely a result of the company's strategic partnerships and innovative approach to servicing both direct payer clients and outpatient care centers. 3. **Overall Financial Performance**: InfuSystem reported record net revenues of $134.9 million for Q4 and full year 2024, marking a 7% year-over-year increase. The company's performance showed significant improvements across key metrics, including adjusted EBITDA and gross margin. In summary, InfuSystem's ability to leverage its service segments, strategic partnerships, and innovative solutions contributed to its strong financial performance, exceeding market forecasts.